Ignite Creation Date:
2025-12-24 @ 10:36 PM
Ignite Modification Date:
2026-02-10 @ 8:42 AM
Study NCT ID:
NCT05972135
Status:
RECRUITING
Last Update Posted:
2025-10-29
First Post:
2023-07-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Sponsor:
SCRI Development Innovations, LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Myeloma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Teclistamab (TECVAYLI™) | View |
| None | Humanized IgG-4 PAA bispecific antibody | View |
| None | CD3 receptor complex | View |
| None | RRMM-Relapsed or Refractory Multiple Myeloma | View |
| None | MM-Multiple Myeloma | View |
| None | Tocilizumab prophylaxis | View |
| None | CRS- Cytokine Release Syndrome | View |
| None | Neurologic toxicity | View |
| None | ICANS-Immune Effector Cell-associated Neurotoxicity Syndrome | View |
| None | Talquetamab (TALVEY™) | View |
| None | GPRC5D | View |
| None | BCMA | View |